|1.||Dixon, Ross: 2 articles (08/2005 - 04/2002)|
|2.||Guns, E S: 2 articles (10/2001 - 06/2000)|
|3.||Mayer, L D: 2 articles (10/2001 - 06/2000)|
|4.||Dixon, R: 2 articles (10/2001 - 06/2000)|
|5.||Gerinec, A: 1 article (08/2011)|
|6.||Babal, P: 1 article (08/2011)|
|7.||Kobzová, D: 1 article (08/2011)|
|8.||Kostolná, B: 1 article (08/2011)|
|9.||Gelmon, Karen A: 1 article (08/2005)|
|10.||Sikic, Branimir: 1 article (08/2005)|
04/01/2002 - "The MDR modulator, OC144-093, is a potential candidate for use in cancer therapy and exhibits potent biological activity in vitro and in vivo when combined with anticancer agents such as paclitaxel. "
08/01/2005 - "A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer."
10/01/2001 - "The novel substituted imidazole compound, OC144-093 exhibits potent biological activity in vitro and in vivo for reversal of P-glycoprotein (PgP) based resistance to cancer chemotherapy. "
11/01/2002 - "Ontogen is developing ONT-093 (formerly OC-144-093), a P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2000 - "OC144-093 increased the life span of doxorubicin-treated mice engrafted with MDR P388 leukemia cells by >100% and significantly enhanced the in vivo antitumor activity of paclitaxel in MDR human breast and colon carcinoma xenograft models, without a significant increase in doxorubicin or paclitaxel toxicity. "
|4.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)